Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –
– Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued –
Related news for (CARA)
- Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
- Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
- 24/7 Market News Snapshot 18 December, 2024 – Cara Therapeutics, Inc. (NASDAQ:CARA)
- Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement